Enzalutamide Bdenza 40mg - Anticancer drugs | BRD | MHP

                                           BDENZA

DESCRIPTION

          Enzalutamide is an active ingredient of Bdenza 40mg tablets available in the strength of 40mg. Bdenza 40mg tablets are used to treat the metastatic prostate cancer, in men. Bdenza 40mg is exhibits its action by stopping the advancement of tumor cells by blockade of androgen hormones especially testosterone.

          Bdenza 40mg containing Enzalutamide is also categorized as an anti-androgen chemo medicine. Bdenza 40mg tablets is not self medication; it is used under the knowledge of medical oncologist.

Bdenza 40mg

BDENZA 40MG TABLETS USES

        Bdenza 40mg tablets are prescribing for; Metastatic or long lasting castration resistant prostate cancer

BDENZA 40MG TABLETS MECHANISM

        Bdenza 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Bdenza 40mg tablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA. The major metabolite of Bdenza is N-desmethyl Enzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Bdenza is exposed by depleting
the multiplication and persuades cell lysis in prostate cancer cells.

PRODUCT DETAILS

Brand : Bdenza
Ingredients : Enzalutamide
Strength : 40mg
Manufactured : BDR pharmaceuticals
Package : 28 Tablets

PHARMACOKINETICS

           The peak plasma concentration time of Bdenza 40mg tablets occurs at 1 hour with the range of 0.5 to 3 hours). The steady state of Bdenza 40mg occurs in day 28. The volume of distribution occur after single dose of Bdenza 40mg tablets is 110L Bdenza 40mg has highly bounds to the human plasma protein with the range of 97 to 98%.

           The major metabolite of Enzalutamide is N-desmethyl Enzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethyl Enzalutamide. Bdenza 40mg tablets is majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces. The terminal half life period of Bdenza 40mg tablet is occurs after a single dose at 5.8days and N-desmethyl Enzalutamide is taken 7.8 to 8.6 days.

DOSAGE MANAGEMENT

            The usual recommended dosage of Bdenza 40mg is 160mg, but available strength of Bdenza 40mg Four tablets of Bdenza 40mg should be taken at a time as a single dose. Bdenza 40mg tablet should be administered with or without food.

            Dosing alteration: In ≥ grade 3 toxicity or extreme side effects: Postpone the dose of Bdenza 40mg tablets for 1 week or as far as symptoms progress to ≤ grade 2, continue at the same or reduced to 120mg or 80mg. Concurrent use with strong CYP2C8 inhibitors:

             In case of combination with strong CYP2C8 inhibitors, diminish the dose of Bdenza 40mg to 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Bdenza 160mg to 240mg as a single dose.
BDENZA 40MG TABLETS SAFETY PRECAUTIONS

The major adverse effect during the therapy of Bdenza 40mg tablets are;

The major adverse effect during the therapy of Bdenza 40mg tablets are;

SEIZURE

       Seizure may produce during the treatment with Bdenza 40mg tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition, patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME PRES

           Patient who are all taking Bdenza 40mg tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension. PRES diagnosed by MRI. If patient acquired with PRES, discontinue the Bdenza therapy

BDENZA 40MG TABLETS CAUSING SIDE EFFECT

         Asthenia Peripheral edema Back pain, arthralgia Musculoskeletal pain Muscular weakness Musculoskeletal stiffness Diarrhea Hot flush Hypertension Headache Dizziness Spinal cord compression Caude equine syndrome Paresthesia Mental disorders Hypoesthesia Respiratory tract infections Insomnia Anxiety Hematuria Pollakiuria Non pathologic fractures Pruritus Dry skin Epistaxis

PREGNANCY & LACTATION:

        The pregnancy category of Bdenza tablet is X Bdenza 40mg tablets are contraindicated to pregnancy conditions; it may cause fetal harm even to death. Bdenza 40mg tablets are contraindicated in lactation period, breast feeding should not be recommended.

STORAGE :

       The storage condition of Bdenza 400mg tablets container at 20°C to 25°C (68°F to 77°F). Container should be kept at dry and cool place.

MISSED DOSE:

        Bdenza 40mg is a chemo tablets, if patient fail to take the dose of Bdenza 40mg tablets must be consult with medical oncologist and take the dose within a time. In any other way the missed dose should be avoid and follow the regular dosing schedule.

OVER DOSAGE

       In case of over dosage of Bdenza 400mg tablets, patients must provided with some supportive measures and discontinue the therapy. The half life of Bdenza 40mg is occurs for 5.8 days. Seizure is the major adverse effect occurred due to over dosage of Bdenza 40mg tablets . Seizure is not described at ≤240mg daily; since three seizures occurs at 360mg, 480mg and 600mg daily.

CONTACT DETAILS

Email :   millionhealthpharmaceuticals@gmail.com
Phone Number :  +91-9940472902

Website :    https://millionpharma.com/bdenza.php